Holen Sie sich die Stockscreener-App
26.52
1.38%
-0.38
Schlusskurs vom Vortag:
$26.90
Offen:
$26.84
24-Stunden-Volumen:
1.12M
Relative Volume:
0.64
Marktkapitalisierung:
$16.29B
Einnahmen:
$3.91B
Nettoeinkommen (Verlust:
$823.88M
KGV:
20.00
EPS:
1.3262
Netto-Cashflow:
$875.28M
1W Leistung:
+0.38%
1M Leistung:
-9.45%
6M Leistung:
-12.33%
1J Leistung:
+35.01%
1-Tages-Spanne:
$26.44
$26.96
1-Wochen-Bereich:
$25.92
$27.23
52-Wochen-Spanne:
$19.59
$35.43
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
26.53 | 16.30B | 3.91B | 823.88M | 875.28M | 1.3262 |
VRTX
Vertex Pharmaceuticals Inc
|
436.33 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.94 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.62 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.22 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.91 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Hochstufung | Goldman | Neutral → Buy |
| 2026-03-27 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-02 | Eingeleitet | Wells Fargo | Overweight |
| 2026-02-17 | Fortgesetzt | Jefferies | Buy |
| 2026-02-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-04-01 | Herabstufung | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-04 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-12-06 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Hochstufung | DNB Markets | Sell → Buy |
| 2023-10-18 | Eingeleitet | Exane BNP Paribas | Underperform |
| 2023-09-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Eingeleitet | BTIG Research | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-31 | Eingeleitet | UBS | Neutral |
| 2023-05-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-12-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-11-14 | Eingeleitet | William Blair | Mkt Perform |
| 2022-11-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-05-02 | Eingeleitet | Cowen | Market Perform |
| 2022-03-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-12-01 | Eingeleitet | Berenberg | Sell |
| 2021-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-01-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Herabstufung | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-06-25 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-08-12 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Genmab Adr Aktie (GMAB) Neueste Nachrichten
Genmab stock (DK0010272202): Analyst sentiment shifts as earnings forecasts decline - AD HOC NEWS
Oppenheimer Asset Management Inc. Acquires 48,894 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Pictet Asset Management Holding SA Takes $33.84 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab ADR shows improved relative strength; still shy of benchmark - MSN
BioNTech (BNTX) surges 6.1%: Is this an indication of further gains? - MSN
Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - GlobeNewswire Inc.
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031Insight on More than 550 Clinical Trials - GlobeNewswire Inc.
Genmab A/S Sponsored ADR $GMAB Shares Bought by Assetmark Inc. - MarketBeat
Genmab A/S Share Capital Reduction - GlobeNewswire Inc.
GMAB Stock Price, Quote & Chart | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Sahm
827,217 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Perpetual Ltd - marketbeat.com
JPMorgan Chase & Co. Decreases Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Arrowpoint Investment Partners Singapore Pte. Ltd. Takes Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab AS (ADR) (US3723032062.SG) Q1 FY2025 earnings call transcript - Yahoo Finance
Terra Nova Asset Management LLC Invests $1.87 Million in Genmab A/S Sponsored ADR $GMAB - MarketBeat
This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Sahm
Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches - Yahoo Finance
Alliancebernstein L.P. Has $335.96 Million Stock Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Genmab A/ S: The Biotech Stock Gen Z Is Quietly Watching - AD HOC NEWS
Russell Investments Group Ltd. Has $25.23 Million Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
First Trust Advisors LP Sells 82,922 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
GMAB Earnings History & Surprises | EPS & Revenue Results | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN
Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case - ChartMill
Stocks With Rising Relative Strength: Genmab ADR - Investor's Business Daily
MSN - MSN
Genmab ADR Shows Improved Relative Strength; Still Shy Of Benchmark - Investor's Business Daily
What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World
GENMAB A/S -SP ADR (NASDAQ:GMAB) Emerges as a Peter Lynch-Style GARP Investment - ChartMill
Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales - Finviz
Genmab A/S (NASDAQ:GMAB) Given New $40.00 Price Target at HC Wainwright - Defense World
Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1 - Sahm
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Genmab A/S (NASDAQ:GMAB) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Genmab A/S Q4 Earnings Call Highlights - Yahoo Finance
Genmab A/S (NASDAQ:GMAB) Given Equal Weight Rating at Morgan Stanley - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Sees Significant Decrease in Short Interest - MarketBeat
279,932 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Cibc World Market Inc. - MarketBeat
Is the Options Market Predicting a Spike in Genmab Stock? - TradingView
H.C. Wainwright Bullish on Genmab A/S (GMAB) on Robust Sales for DARZALEX - Finviz
Envestnet Asset Management Inc. Purchases 60,336 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
RFG Advisory LLC Takes $1.30 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Where is Genmab A/S (GMAB) Headed According to Wall Street? - Finviz
Oppenheimer Asset Management Inc. Acquires 61,311 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth - ChartMill
Finanzdaten der Genmab Adr-Aktie (GMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Genmab Adr-Aktie (GMAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
2,978 |
288,866 |
72,831,487 |
| GENMAB A/S | 10% Owner |
Dec 23 '25 |
Buy |
97.00 |
561,042 |
54,421,074 |
72,589,817 |
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
142,610 |
13,833,170 |
72,828,509 |
| GENMAB A/S | 10% Owner |
Dec 24 '25 |
Buy |
97.00 |
96,082 |
9,319,954 |
72,685,899 |
| GENMAB A/S | 10% Owner |
Dec 22 '25 |
Buy |
97.00 |
15,710 |
1,523,870 |
72,028,775 |
| GENMAB A/S | 10% Owner |
Dec 18 '25 |
Buy |
97.00 |
212,177 |
20,581,169 |
71,946,801 |
| GENMAB A/S | 10% Owner |
Dec 19 '25 |
Buy |
97.00 |
66,264 |
6,427,608 |
72,013,065 |
| GENMAB A/S | 10% Owner |
Dec 17 '25 |
Buy |
97.00 |
150,795 |
14,627,115 |
71,734,624 |
| GENMAB A/S | 10% Owner |
Dec 16 '25 |
Buy |
97.00 |
120,752 |
11,712,944 |
71,583,829 |
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):